Motley Fool Australia

Telix Pharmaceuticals Ltd (ASX: TLX) Share Price and News

Price
Movement
52 Week Range
-
1 Year Return
(20 mins delayed)

() Chart and Price Data

.

Share Price
Previous Close
Volume
Day Change
Open
Monthly Average Volume
52 Week Range -
Days Range -
Turnover

Fundamental Company Figures

Data provided by Morningstar.
Market Cap $1.11 billion
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 281.37 million
Earnings per share -0.175
Dividend per share N/A
Year To Date Return 4.23%
Earnings Yield N/A
Franking N/A

Telix Pharmaceuticals Ltd (ASX: TLX) Latest News

rising medical asx share price represented by FDA approval stamp

Why the Telix (ASX:TLX) share price is surging 8%

More »

Downward trend

Why IDP Education, Sandfire, Telix, & Treasury Wine shares are dropping lower

More »

shares valuation higher upgrade, growth shares

Why Abacus, Amaysim, CSR, & Telix shares stormed higher today

More »

man jumping along increasing bar graph signifying jump in alumina share price

Telix (ASX:TLX) share price jumps 30% to an all-time high. Here’s why.

More »

Why Baby Bunting, Northern Star, Oil Search, & Telix shares are storming higher

More »

Rising ASX share price represented by investors jumping high in the air

Telix (ASX:TLX) share price jumps 8% higher on FDA update

More »

Red and white arrows showing share price drop

Why Atlas Arteria, Cochlear, Telix, & Treasury Wine shares are dropping lower

More »

man jumps up a chart, indicating share price going up on the ASX bank dividend

Why Iron Road, Nuchev, Telix, & Treasury Wine shares are pushing higher today

More »

About Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.

Share Price History

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
07 May 2021 $3.94 $0.01 0.25% 298,819 $3.85 $4.00 $3.85
06 May 2021 $3.93 $0.04 1.03% 264,722 $3.94 $3.98 $3.89
05 May 2021 $3.89 $-0.01 -0.26% 475,918 $3.89 $3.95 $3.83
04 May 2021 $3.90 $0.12 3.17% 547,023 $3.94 $3.99 $3.86
03 May 2021 $3.78 $0.04 1.07% 436,097 $3.74 $3.82 $3.70
30 Apr 2021 $3.74 $0.00 0.00% 332,297 $3.75 $3.77 $3.70
29 Apr 2021 $3.74 $0.01 0.27% 764,548 $3.80 $3.81 $3.70
28 Apr 2021 $3.73 $0.00 0.00% 486,999 $3.76 $3.77 $3.70
27 Apr 2021 $3.73 $-0.07 -1.84% 875,120 $3.81 $3.90 $3.71
26 Apr 2021 $3.80 $-0.10 -2.56% 313,552 $3.98 $3.98 $3.80
23 Apr 2021 $3.90 $-0.08 -2.01% 524,304 $3.97 $4.03 $3.89
22 Apr 2021 $3.98 $0.02 0.51% 451,978 $3.97 $4.02 $3.87
21 Apr 2021 $3.96 $0.05 1.28% 622,679 $3.92 $3.96 $3.84
20 Apr 2021 $3.91 $-0.10 -2.49% 613,597 $4.09 $4.10 $3.90
19 Apr 2021 $4.01 $0.04 1.01% 394,258 $4.10 $4.18 $4.01
16 Apr 2021 $3.97 $-0.10 -2.46% 641,047 $4.08 $4.08 $3.92
15 Apr 2021 $4.07 $0.01 0.25% 257,055 $4.17 $4.20 $4.03
14 Apr 2021 $4.06 $0.02 0.50% 487,088 $4.15 $4.25 $4.06
13 Apr 2021 $4.04 $-0.03 -0.74% 233,761 $4.07 $4.17 $4.02
12 Apr 2021 $4.07 $-0.18 -4.24% 465,510 $4.20 $4.25 $4.07
09 Apr 2021 $4.25 $0.06 1.43% 297,054 $4.26 $4.29 $4.19
08 Apr 2021 $4.19 $0.00 0.00% 697,956 $4.21 $4.29 $4.14
Show more

Director Transactions

Data provided by Morningstar.
Date Director Type Amount Value Notes
02 Nov 2020 Oliver Buck Exercise 165 $140,530
02 Nov 2020 Oliver Buck Buy 165 $140,530
12 May 2020 Christian Behrenbruch Issued 200 $294,000


Directors & Management

Data provided by Morningstar.
Name Title StartDate Profile
Mr Harry Kevin McCann Non-Executive Chairman,Non-Executive Director Sep 2017
Ms Jann E Skinner Non-Executive Director Jun 2018
Dr Christian Peter Behrenbruch Chief Executive Officer,Managing Director Jan 2017
Dr Andreas Kluge Non-Executive Director Jan 2017
Mr Oliver Buck Non-Executive Director Jan 2017
Dr Mark Alexander Nelson Non-Executive Director Sep 2017
Ms Melanie Farris Chief Governance & Risk Officer,Company Secretary Mar 2017
David Cade Chief Business Officer & Head of Investor Relations
Melanie Farris Chief Governance & Risk Officer,Company Secretary
Colin Hayward Chief Medical Officer
Jonathan Barlow General Counsel
Margaret Haarhoff Global Director of People & Culture
Michael Larcom Global Director of Quality
Doug Cubbin Group Chief Financial Officer
Gabriel Liberatore Group Chief Operating Officer
Ludovic Wouters President, Telix Europe
Shintaro Nishimura President, Telix Japan
Bernard Lambert President, Telix US
Tracey Brown SVP Global Clinical Operations
Sunil Kadam SVP Global Regulatory Affairs
Show more

Top Share Holders

Data provided by Morningstar.
Name Shares Capital
HSBC Custody Nominees (Australia) Limited 37,477,609 13.37%
ELK River Holdings Pty Ltd 24,675,000 8.80%
Gnosis Verwaltungsgesellschaftm B H 24,675,000 8.80%
Grand Decade Developments Limited 20,947,181 7.47%
J P Morgan Nominees Australia Pty Limited 8,371,563 2.99%
UV Cap Gmbh & Co Kg 7,775,000 2.77%
BNP Paribas Noms Pty Ltd 6,904,087 2.46%
The Oncidium Foundation 6,470,392 2.31%
National Nominees Limited 6,361,306 2.27%
Citicorp Nominees Pty Limited 6,249,988 2.23%
Scintec Diagnostics Gmbh 4,312,151 1.54%
BNP Paribas Nominees Pty Ltd 3,782,218 1.35%
UBS Nominees Pty Ltd 3,029,153 1.08%
HSBC Custody Nominees (Australia) Limited A/C 2 2,843,462 1.01%
Jean Marc Le Doussal 2,750,000 0.98%
Ilusa Sprl 2,558,138 0.91%
Yelwac Pty Ltd 2,381,804 0.85%
Man Holdings Pty Ltd 2,238,750 0.80%
Telix Pharmaceuticals (Est) Pty Ltd 2,115,000 0.75%
Aglub Investments Pty Ltd 1,933,342 0.69%
Jean Francois Chatal 1,797,795 0.64%
Show more